Gozellix is a drug owned by Telix Innovations Sa. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2035. Details of Gozellix's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11027031 | Kit for radiolabelling |
Jul, 2035
(10 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Gozellix is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gozellix's family patents as well as insights into ongoing legal events on those patents.
Gozellix's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gozellix's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gozellix Generics:
There are no approved generic versions for Gozellix as of now.
Alternative Brands for Gozellix
There are several other brand drugs in the same treatment category and using the same active ingredient (Gallium Ga-68 Gozetotide) as Gozellix. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Telix |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Gallium Ga-68 Gozetotide. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Novartis |
|
About Gozellix
Gozellix is a drug owned by Telix Innovations Sa. Gozellix uses Gallium Ga-68 Gozetotide as an active ingredient. Gozellix was launched by Telix Innovations in 2025.
Approval Date:
Gozellix was approved by FDA for market use on 20 March, 2025.
Active Ingredient:
Gozellix uses Gallium Ga-68 Gozetotide as the active ingredient. Check out other Drugs and Companies using Gallium Ga-68 Gozetotide ingredient
Dosage:
Gozellix is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | POWDER | Prescription | INTRAVENOUS |